Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.48 |
| ▸ | NMT2 | O60551 | 5/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25062575 | 0.90 | SIRT6 (0.53) | NMT1NMT2TLR2CHRNB2CHRNB4 | |
| SCHEMBL25062579 | 0.89 | NMT1 (0.46) | NMT1NMT2ROCK2CALCRLPRKACA | |
| SCHEMBL24983625 | 0.86 | NMT2 (0.41) | NMT1NMT2PTGS1PTGS2 | |
| SCHEMBL17325767 | 0.85 | SIRT6 (0.48) | NMT1NMT2ROCK2PRKACAAKT3 | |
| SCHEMBL254293 | 0.85 | SIRT6 (0.48) | NMT1NMT2ROCK2PRKACAAKT3 | |
| SCHEMBL16152402 | 0.84 | GLP1R (0.41) | NMT1NMT2ROCK2PTGS1PTGS2 | |
| SCHEMBL23482534 | 0.84 | PTGS1 (0.52) | PTGS1PTGS2 | |
| SCHEMBL7996266 | 0.84 | SLC6A5 (0.50) | PTGS1PTGS2 | |
| SCHEMBL23451312 | 0.84 | PTGS1 (0.52) | PTGS1PTGS2 | |
| SCHEMBL25130218 | 0.84 | PTGS1 (0.52) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | NMT1 15/4885NMT2 38/4885ROCK2 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.